CTIS2023-507428-21-00进行中（未招募）1 期
b1-23-CIDg
Alkaloid AD Skopje0 个研究点目标入组 50 人开始时间: 2023年8月28日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Conducting a quality study of the medicinal product - Vortioxetineo therapeutic indication in the current trial with healthy volunteers. The intended indication is for the treatment of major depressive episodes in adultsMedDRA version: 21.1Level: LLTClassification code: 10081270Term: Major depressive disorder Class: 10037175CTIS2023-509946-36-00CCDRD Cooperative Clinical Drug Research and Development AG36
进行中（未招募）
1 期
Comparative Bioavailability of Midazolam 7.5 mg/1.5 mL Oromucosal Solution (Buccolam®) Versus 10 mg/2 mL Solution for Injection (Hypnovel®) in Healthy Subjects.o medical condition.CTIS2023-504903-10-00aboratorios Lesvi S.L.24
进行中（未招募）
1 期
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)Diffuse large B-cell lymphoma (DLBCL), Grade 3B follicular lymphoma, High grade B-cell lymphoma (HGBL), Epstein-Barr virus-positive DLBCLMedDRA version: 21.0Level: PTClassification code: 10012818Term: Diffuse large B-cell lymphoma Class: 100000004864CTIS2023-507497-40-00F. Hoffmann-La Roche AG50
进行中（未招募）
1 期
A phase 1 study of FluBHPVE6E7 immunotherapy in patients with HPV16-associated oropharyngeal squamous cell carcinomaTreatment of human papilloma virus (HPV) associated infections and cancersMedDRA version: 20.1Level: LLTClassification code: 10063001Term: Human papilloma virus infection Class: 10021881CTIS2024-514413-36-00Bluesky Immunotherapies GmbH12
进行中（未招募）
1 期
AN OPEN LABEL, TWO PERIODS, TWO SEQUENCES, CROSSOVER, RANDOMIZED MULTIPLE DOSE BIOEQUIVALENCE STUDY OF GUANFACINE 7 MG PROLONGED-RELEASE TABLETS (TEST FORMULATION) VS. EQUAL DOSE OF INTUNIV® PROLONGED-RELEASE TABLETS (REFERENCE FORMULATION) IN HEALTHY MALE VOLUNTEERS UNDER FASTING CONDITIONSStudy performed on healthy volunteers.CTIS2023-506596-10-00neuraxpharm Arzneimittel GmbH42